ArticleInternational journal of molecular sciences2026
Endocan Participates in TGF-β/Smad and AKT/ERK Signaling Coordination and lncRNA Modulation in Human Cardiac Fibroblasts.
Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Endocan, a soluble dermatan sulfate proteoglycan, is increasingly recognized as a regulator of key cellular pathways in both physiological and pathological contexts. While TGF-β is a central mediator of fibrotic remodeling, the role of endocan in this process remains elusive. By performing a transcriptomic dataset analysis [GSE116250], we found that endocan expression is upregulated and correlates with fibrotic markers in human failing hearts. We investigated the role of endocan in an in vitro model of cardiac fibroblasts stimulated with TGF-β. Our results identified endocan as a TGF-β-responsive gene in primary human cardiac fibroblasts. Indeed, by inhibiting endocan expression using a specific siRNA, we demonstrated that this proteoglycan is required for the full expression of key fibrosis-related genes (Col1a1, α-SMA, MMP-3, and MMP-9) and modulates the expression of long non-coding RNAs (MALAT1, H19 and HOTAIR), which are essential for the epigenetic control of the fibroblast phenotype. These effects depend on the modulation of both canonical (SMAD3) and non-canonical (AKT and ERK1/2) TGF-β pathways. Taken together, these findings indicate that endocan is required for the coordinated activation of canonical and non-canonical TGF-β signaling during fibroblast transdifferentiation and suggest its potential involvement in the molecular mechanisms underlying cardiac fibrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.